The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004
Evaluation of airway sGaw in Japanese COPD patients treated with triple therapy using salmeterol/fluticasone propionate 50/250 and tiotropium bromide Source: International Congress 2015 – COPD: interesting notes Year: 2015
Effects of budesonide/formoterol combination therapy versus budesonide on airway dimensions in asthma Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012
Stable dosing with salmeterol/fluticasone propionate combination ensures long-term asthma control, including airway hyperresponsiveness Source: Eur Respir J 2005; 26: Suppl. 49, 429s Year: 2005
Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010
Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
The effects of treatment with fluticasone propionate alone and combination with salmeterol on asthma control and airway inflammation Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003
Combination therapy with maintenance budesonide and formoterol in COPD Source: Eur Respir J 2004; 24: 1070 Year: 2004
Asthma exacerbation with fluticasone propionate/formoterol fumarate combination therapy versus its individual components Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
Effect of discontinuation of inhaled fluticasone propionate on exacerbations in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 183s Year: 2001
Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Predicting factors for an exacerbation in patients with COPD during one year treatment with salmeterol/fluticasone or salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 512s Year: 2004
Dynamics of lung function in children treated with salmeterol/ fluticasone propionate combination (SFC) Source: Eur Respir J 2003; 22: Suppl. 45, 497s Year: 2003
Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017
Effect of fluticasone and formoterol combination therapy on airway remodeling Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
Lung function and symptom improvement with fluticasone/salmeterol and ipratropium/albuterol in albuterol responsive and non-responsive COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 89s Year: 2004
Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life Source: Eur Respir J 2003; 22: Suppl. 45, 51s Year: 2003
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001